Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study
Abstract Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of...
Main Authors: | Jon Berner, Animesh Acharjee |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2024-04-01
|
Series: | Discover Mental Health |
Online Access: | https://doi.org/10.1007/s44192-024-00066-5 |
Similar Items
-
Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion
by: Ruin Moaddel, et al.
Published: (2023-12-01) -
Magnesium in Ketamine Administration in Treatment-Resistant Depression
by: Natalia Górska, et al.
Published: (2021-05-01) -
Ketamine cystitis following ketamine therapy for treatment-resistant depression – case report
by: Minna Chang, et al.
Published: (2024-01-01) -
Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression
by: Maria Gałuszko-Węgielnik, et al.
Published: (2023-01-01) -
An exploration of actigraphy in the context of ketamine and treatment‐resistant depression
by: Claire Punturieri, et al.
Published: (2024-03-01)